(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
German men need approval for stays abroad under military service law - 2Is Trump going to war with Venezuela?
- 3Go on A Careful spending plan: Modest Objections for Your List of must-dos
- 4Remote Headphones: Upgrade Your Sound Insight
- 5Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- 5 Instructive Toy Brands for Youngsters
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Must-Have Cooking Machine in Your Kitchen
- Instructions to Explore the Universe of Vehicle Leases
- Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
- 6 Arranging Administrations to Change Your Open air Space
- No more attempts to free whale stranded off Germany, officials say
- Why More Couples Are Choosing Africa For Their Honeymoon
